FibroGen (FGEN) Tops Q3 EPS by 21c

Go back to FibroGen (FGEN) Tops Q3 EPS by 21c

FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update

November 8, 2016 4:03 PM EST

Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD

Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time

SAN FRANCISCO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a research-based biopharmaceutical company, today reported financial results for the quarter ended September 30, 2016 and provided an update on the companys recent developments.

The completion of enrollment in our Phase 3 roxadustat studies in China is a... More